001018540 001__ 1018540
001018540 005__ 20240311125737.0
001018540 0247_ $$2doi$$a10.1212/WNL.0000000000207622
001018540 0247_ $$2ISSN$$a0028-3878
001018540 0247_ $$2ISSN$$a1526-632X
001018540 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-04868
001018540 0247_ $$2pmid$$a37487750
001018540 0247_ $$2WOS$$aWOS:001158672700001
001018540 037__ $$aFZJ-2023-04868
001018540 082__ $$a610
001018540 1001_ $$0P:(DE-HGF)0$$aSchweitzer, Finja$$b0
001018540 245__ $$aProgressive Multifocal Leukoencephalopathy
001018540 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2023
001018540 3367_ $$2DRIVER$$aarticle
001018540 3367_ $$2DataCite$$aOutput Types/Journal article
001018540 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705497823_25936
001018540 3367_ $$2BibTeX$$aARTICLE
001018540 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001018540 3367_ $$00$$2EndNote$$aJournal Article
001018540 520__ $$aJC polyomavirus (JCV) establishes an asymptomatic latent and/or persistent infection in most of the adult population. However, in immunocompromised individuals, JCV can cause a symptomatic infection of the brain, foremost progressive multifocal leukoencephalopathy (PML). In the past 2 decades, there has been increasing concern among patients and the medical community because PML was observed as an adverse event in individuals treated with modern (selective) immune suppressive treatments for various immune-mediated diseases, especially multiple sclerosis. It became evident that this devastating complication also needs to be considered beyond the patient populations historically at risk, including those with hematologic malignancies or HIV-infected individuals. We review the clinical presentation of PML, its variants, pathogenesis, and current diagnostic approaches. We further discuss the need to validate JCV-directed interventions and highlight current management strategies based on early diagnosis and restoring JCV-specific cellular immunity, which is crucial for viral clearance and survival. Finally, we discuss the importance of biomarkers for diagnosis and response to therapy, instrumental in defining sensitive study end points for successful clinical trials of curative or preventive therapeutics. Advances in understanding PML pathophysiology, host and viral genetics, and diagnostics in conjunction with novel immunotherapeutic approaches indicate that the time is right to design and perform definitive trials to develop preventive options and curative therapy for JCV-associated diseases.
001018540 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001018540 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001018540 7001_ $$0P:(DE-HGF)0$$aLaurent, Sarah$$b1
001018540 7001_ $$0P:(DE-HGF)0$$aCortese, Irene$$b2
001018540 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b3
001018540 7001_ $$0P:(DE-HGF)0$$aSilling, Steffi$$b4
001018540 7001_ $$00000-0001-8550-335X$$aSkripuletz, Thomas$$b5
001018540 7001_ $$0P:(DE-HGF)0$$aMetz, Imke$$b6
001018540 7001_ $$0P:(DE-HGF)0$$aWattjes, Mike P.$$b7
001018540 7001_ $$00000-0002-3510-9255$$aWarnke, Clemens$$b8$$eCorresponding author
001018540 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000207622$$gVol. 101, no. 16, p. 700 - 713$$n16$$p700 - 713$$tNeurology$$v101$$x0028-3878$$y2023
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.pdf$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/post-print.pdf$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.gif?subformat=icon$$xicon$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-1440$$xicon-1440$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-180$$xicon-180$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/PDF%20restricted.jpg?subformat=icon-640$$xicon-640$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/post-print.gif?subformat=icon$$xicon$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-1440$$xicon-1440$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-180$$xicon-180$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 8564_ $$uhttps://juser.fz-juelich.de/record/1018540/files/post-print.jpg?subformat=icon-640$$xicon-640$$yPublished on 2023-10-17. Available in OpenAccess from 2024-10-17.
001018540 909CO $$ooai:juser.fz-juelich.de:1018540$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001018540 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
001018540 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001018540 9141_ $$y2023
001018540 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
001018540 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-21$$wger
001018540 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
001018540 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
001018540 920__ $$lyes
001018540 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001018540 980__ $$ajournal
001018540 980__ $$aVDB
001018540 980__ $$aUNRESTRICTED
001018540 980__ $$aI:(DE-Juel1)INM-3-20090406
001018540 9801_ $$aFullTexts